Classification/NN
of/IN
Human/JJ
Papillomavirus/NN
(/(
HPV/NN
)/)
Risk/NN
Type/NN
via/IN
Text/JJ
Mining/NN
./.
====================
Human/JJ
Papillomavirus/NN
(/(
HPV/NN
)/)
infection/NN
is/VBZ
known/VBN
as/IN
the/DT
====================
main/JJ
factor/NN
for/IN
cervical/JJ
cancer/NN
which/WDT
is/VBZ
a/DT
leading/VBG
cause/VBP
of/IN
cancer/NN
deaths/NNS
in/IN
women/NNS
worldwide/NN
./.
====================
Because/IN
there/EX
are/VBP
more/RBR
than/IN
100/CD
types/NNS
in/IN
HPV/NN
,/,
it/PRP
is/VBZ
critical/JJ
to/TO
discriminate/VB
the/DT
HPVs/NNS
related/JJ
with/IN
cervical/JJ
cancer/NN
from/IN
those/DT
not/RB
related/JJ
with/IN
it/PRP
./.
====================
In/IN
this/DT
paper/NN
,/,
the/DT
risk/NN
type/NN
of/IN
HPVs/NNS
using/VBG
their/PRP$
textual/JJ
explanation/NN
./.
====================
The/DT
important/JJ
issue/NN
in/IN
this/DT
problem/NN
is/VBZ
to/TO
distinguish/VB
false/VBP
negatives/NNS
from/IN
false/NN
positives/VBZ
./.
====================
That/DT
is/VBZ
,/,
we/PRP
must/MD
find/VBP
high-risk/VBP
HPVs/NNS
as/IN
many/JJ
as/IN
possible/JJ
though/IN
we/PRP
may/MD
miss/VB
some/DT
low-risk/JJ
HPVs/NNS
./.
====================
For/IN
this/DT
purpose/NN
,/,
the/DT
AdaCost/NN
,/,
a/DT
cost-sensitive/JJ
learner/NN
is/VBZ
adopted/VBN
to/TO
consider/VB
different/JJ
costs/NNS
between/IN
training/VBG
examples/NNS
./.
====================
The/DT
experimental/JJ
results/NNS
on/IN
the/DT
HPV/NN
sequence/NN
database/NN
show/VBP
that/IN
the/DT
consideration/NN
of/IN
costs/NNS
gives/VBZ
higher/JJR
performance/NN
./.
====================
The/DT
improvement/JJ
in/IN
F-score/NN
is/VBZ
higher/JJR
than/IN
that/DT
of/IN
the/DT
accuracy/NN
,/,
which/WDT
implies/VBZ
that/IN
the/DT
number/NN
of/IN
high-risk/JJ
HPVs/NNS
found/VBN
is/VBZ
increased/VBN
./.
====================
Cervical/JJ
cancer/NN
is/VBZ
a/DT
leading/VBG
cause/VBP
of/IN
cancer/NN
deaths/NNS
in/IN
women/NNS
worldwide/NN
./.
====================
It/PRP
,/,
moreover/RB
,/,
is/VBZ
the/DT
first/JJ
cause/VBP
of/IN
cancer/NN
deaths/NNS
in/IN
Korean/JJ
women/NNS
./.
====================
Since/IN
the/DT
main/JJ
etiologic/JJ
factor/NN
for/IN
cervical/JJ
cancer/NN
is/VBZ
known/VBN
as/IN
high-risk/JJ
Human/JJ
Papillomavirus/NN
(/(
HPV/NN
)/)
infection/NN
(/(
Schiffman/NNP
et/FW
al./FW
,/,
1993/CD
)/)
,/,
it/PRP
is/VBZ
now/RB
largely/RB
a/DT
preventable/JJ
disease/NN
./.
====================
HPV/NN
is/VBZ
a/DT
double-strand/JJ
DNA/NN
tumor/NN
virus/NN
that/WDT
belongs/VBZ
to/TO
the/DT
papovavirus/NN
family/NN
./.
====================
There/EX
are/VBP
more/RBR
than/IN
100/CD
types/NNS
of/IN
HPV/NN
that/DT
are/VBP
specific/JJ
for/IN
epithelial/JJ
cells/NNS
including/VBG
skin/NN
,/,
respiratory/JJ
mucosa/NN
,/,
and/CC
the/DT
genital/JJ
tract/NN
./.
====================
Genital/JJ
tract/NN
HPV/NN
types/NNS
are/VBP
classified/VBN
by/IN
their/PRP$
relative/JJ
malignant/JJ
potential/JJ
into/IN
low-risk/JJ
and/CC
high-risk/VBP
types/NNS
(/(
Janicek/NN
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
The/DT
common/JJ
,/,
unifying/VBG
oncogenic/JJ
feature/NN
of/IN
the/DT
vast/JJ
majority/NN
of/IN
cervical/JJ
cancers/NNS
is/VBZ
the/DT
presence/NN
of/IN
high-risk/JJ
HPV/NN
./.
====================
Therefore/RB
,/,
the/DT
most/JJS
important/JJ
thing/JJ
for/IN
diagnosis/NN
and/CC
therapy/NN
is/VBZ
discriminating/JJ
whether/IN
patients/NNS
have/VBP
the/DT
high-risk/JJ
HPVs/NNS
and/CC
what/WP
HPV/NN
types/NNS
are/VBP
highly/RB
risky/NN
./.
====================
One/CD
way/NN
to/TO
discriminate/VB
the/DT
risk/NN
types/NNS
of/IN
HPVs/NNS
is/VBZ
using/VBG
a/DT
text/JJ
mining/JJ
technique/NN
./.
====================
Since/IN
a/DT
great/JJ
number/NN
of/IN
research/NN
results/NNS
on/IN
HPV/NN
have/VBP
been/VBN
already/RB
reported/VBN
in/IN
biomedical/JJ
journals/NNS
(/(
Furumoto/RB
and/CC
Irahara/NN
,/,
2002/CD
;/:
Ishji/NNP
,/,
2000/CD
)/)
,/,
they/PRP
can/MD
be/VB
used/VBN
as/IN
a/DT
source/NN
of/IN
discriminating/VBG
HPV/NN
risk/NN
types/NNS
./.
====================
One/CD
problem/NN
in/IN
discriminating/VBG
the/DT
risk/NN
types/NNS
is/VBZ
that/DT
the/DT
costs/NNS
of/IN
high-risk/JJ
HPVs/NNS
and/CC
low-risk/JJ
HPVs/NNS
are/VBP
not/RB
identical/JJ
./.
====================
This/DT
is/VBZ
because/IN
high-risk/VBP
HPVs/NNS
are/VBP
seldom/JJ
while/IN
low-risk/NN
HPVs/NNS
are/VBP
abundant/JJ
./.
====================
In/IN
addition/NN
,/,
in/IN
classifying/VBG
the/DT
risk/NN
types/NNS
of/IN
HPVs/NNS
,/,
it/PRP
is/VBZ
important/JJ
to/TO
distinguish/VB
false/VBP
negatives/NNS
from/IN
false/JJ
positives/VBZ
./.
====================
That/DT
is/VBZ
,/,
it/PRP
is/VBZ
not/RB
critical/JJ
to/TO
classify/VB
the/DT
low-risk/JJ
HPVs/NNS
as/IN
high-risk/JJ
ones/NNS
,/,
because/IN
they/PRP
can/MD
be/VB
investigated/VBN
by/IN
further/JJ
empirical/JJ
study/NN
./.
====================
However/RB
,/,
it/PRP
is/VBZ
fatal/JJ
to/TO
classify/VB
the/DT
high-risk/JJ
HPVs/NNS
as/IN
low-risk/JJ
ones/NNS
./.
====================
In/IN
this/DT
case/NN
,/,
dangerous/JJ
HPVs/NNS
can/MD
be/VB
missed/VBN
,/,
and/CC
there/EX
is/VBZ
no/DT
further/JJ
chance/NN
to/TO
detect/VB
cervical/JJ
cancer/NN
by/IN
them/PRP
./.
====================
Most/JJS
machine/NN
learning/VBG
algorithms/NNS
for/IN
classification/NN
problems/NNS
have/VBP
focused/VBN
on/IN
minimizing/JJ
the/DT
number/NN
of/IN
incorrect/JJ
predictions/NNS
./.
====================
However/RB
,/,
this/DT
kind/NN
of/IN
learning/VBG
algorithms/NNS
ignores/VBZ
the/DT
differences/NNS
between/IN
different/JJ
types/NNS
of/IN
incorrect/JJ
prediction/NN
cost/JJS
./.
====================
Thus/RB
,/,
recently/RB
,/,
there/EX
has/VBZ
been/VBN
considerable/JJ
interest/NN
in/IN
cost-sensitive/JJ
learning/VBG
(/(
Provost/JJ
and/CC
Fawcett/NN
,/,
1997/CD
)/)
./.
====================
Ting/VBG
and/CC
Zheng/JJ
(/(
1998/CD
)/)
proposed/VBN
two/CD
related/JJ
but/CC
different/JJ
cost-sensitive/JJ
boosting/VBG
approaches/NNS
for/IN
tree/JJ
classification/NN
./.
====================
Their/PRP$
approaches/NNS
can/MD
be/VB
applied/VBN
only/RB
to/TO
situations/NNS
where/WRB
the/DT
costs/NNS
change/NN
very/RB
often/RB
./.
====================
To/TO
apply/RB
boosting/VBG
to/TO
situations/NNS
where/WRB
misclassification/NN
costs/NNS
are/VBP
relatively/RB
stable/JJ
,/,
Fan/JJ
etal/JJ
./.
====================
(/(
1999/CD
)/)
proposed/VBD
the/DT
AdaCost/NN
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
propose/VBP
a/DT
cost-sensitive/JJ
learning/VBG
method/NN
to/TO
classify/VB
the/DT
risk/NN
types/NNS
of/IN
HPVs/NNS
using/VBG
their/PRP$
textual/JJ
explanation/NN
./.
====================
In/IN
classifying/VBG
their/PRP$
risk/NN
types/NNS
,/,
we/PRP
consider/VBP
the/DT
learning/VBG
costs/NNS
of/IN
each/DT
example/NN
,/,
because/IN
it/PRP
is/VBZ
far/RB
more/RBR
important/JJ
to/TO
reduce/VB
the/DT
number/NN
of/IN
false/JJ
negatives/NNS
1/CD
*/DT
than/IN
to/TO
reduce/VB
that/DT
of/IN
false/JJ
positives/VBZ
./.
====================
For/IN
this/DT
purpose/NN
,/,
we/PRP
adopt/VBP
====================
AdaCost/RB
as/IN
a/DT
learning/VBG
algorithm/NN
and/CC
prove/VB
empirically/RB
that/DT
it/PRP
shows/VBZ
great/JJ
performance/NN
in/IN
classifying/VBG
the/DT
HPV/NN
risk/NN
types/NNS
./.
====================
One/CD
advantage/NN
of/IN
this/DT
work/NN
is/VBZ
usefulness/NN
for/IN
designing/VBG
the/DT
DNA-chip/NN
,/,
diagnosing/VBG
the/DT
presence/NN
of/IN
Human/JJ
Papillomavirus/NN
in/IN
cervical/JJ
cancer/NN
patients/NNS
./.
====================
Since/IN
there/EX
are/VBP
about/RB
100/CD
HPV/NN
types/NNS
,/,
making/VBG
the/DT
DNA/NN
chip/NN
needs/VBZ
to/TO
choose/VB
some/DT
dangerous/JJ
ones/NNS
related/JJ
with/IN
cervical/JJ
cancer/NN
among/IN
them/PRP
./.
====================
Therefore/RB
,/,
this/DT
result/NN
classifying/VBG
the/DT
risk/NN
of/IN
HPVs/NNS
can/MD
be/VB
a/DT
big/NN
help/VBP
to/TO
save/VB
time/NN
to/TO
understand/VB
information/NN
about/IN
HPV/NN
and/CC
cervical/JJ
cancer/NN
from/IN
many/JJ
papers/NNS
and/CC
to/TO
choose/VB
the/DT
HPV/NN
types/NNS
used/VBN
for/IN
DNA/NN
chip/NN
./.
====================
The/DT
rest/JJS
of/IN
this/DT
paper/NN
is/VBZ
organized/VBN
as/IN
follows/VBZ
./.
====================
Section/NN
2/CD
expresses/VBZ
the/DT
problems/NNS
of/IN
normal/JJ
machine/NN
learning/VBG
algorithms/NNS
./.
====================
Section/NN
3/CD
describes/VBZ
the/DT
cost-sensitive/JJ
learning/VBG
to/TO
classify/VB
HPV/NN
risk/NN
types/NNS
./.
====================
Section/NN
4/CD
explains/VBZ
how/WRB
the/DT
HPV/NN
dataset/NN
is/VBZ
generated/VBN
./.
====================
Section/NN
5/CD
presents/VBZ
the/DT
experimental/JJ
results/NNS
./.
====================
Finally/RB
,/,
section/NN
6/CD
draws/VBZ
conclusions/NNS
./.
====================
First/RB
,/,
let/NN
us/PRP
check/NN
what/WP
happens/NNS
unless/IN
we/PRP
consider/VBP
the/DT
cost/JJ
of/IN
each/DT
learning/VBG
example/NN
./.
====================
We/PRP
classify/VBP
the/DT
risk/NN
type/NN
of/IN
HPVs/NNS
by/IN
their/PRP$
textual/JJ
explanation/NN
given/VBN
by/IN
Los/NN
Alamos/NN
National/JJ
Laboratory/JJ
./.
====================
The/DT
details/NNS
of/IN
this/DT
explanation/NN
will/MD
be/VB
explained/VBN
in/IN
Section/NN
4/CD
./.
====================
Table/JJ
1/CD
shows/VBZ
the/DT
classification/NN
result/NN
of/IN
HPVs/NNS
according/VBG
to/TO
their/PRP$
risk/NN
types/NNS
./.
====================
It/PRP
is/VBZ
classified/VBN
by/IN
the/DT
naive/JJ
Bayes/NNS
classifier/NN
(/(
Lang/NNP
,/,
1995/CD
)/)
without/IN
considering/VBG
the/DT
costs/NNS
of/IN
the/DT
examples/NNS
./.
====================
This/DT
result/NN
is/VBZ
obtained/VBN
when/WRB
we/PRP
used/VBD
only/RB
seven/CD
HPVs/NNS
as/IN
a/DT
training/JJ
set/NN
./.
====================
Among/IN
the/DT
seven/CD
HPVs/NNS
,/,
five/CD
are/VBP
high-risk/JJ
(/(
HPV16/NN
,/,
HPV18/NN
,/,
HPV31/NN
,/,
HPV33/NN
,/,
HPV45/NN
)/)
,/,
and/CC
the/DT
other/JJ
two/CD
are/VBP
====================
low-risk/JJ
(/(
HPV11/NN
and/CC
HPV6/NN
)/)
./.
====================
Because/IN
the/DT
risk/NN
types/NNS
of/IN
these/DT
HPVs/NNS
are/VBP
well/RB
known/VBN
(/(
Levy/NNP
et/FW
al/JJ
,/,
1994/CD
)/)
,/,
they/PRP
are/VBP
chosen/NN
to/TO
be/VB
a/DT
training/JJ
set/NN
./.
====================
The/DT
number/NN
of/IN
tested/VBN
HPVs/NNS
is/VBZ
69/CD
./.
====================
Assuming/VBG
that/IN
Table/JJ
2/CD
below/IN
is/VBZ
correct/JJ
,/,
the/DT
risk/NN
type/NN
for/IN
four/CD
of/IN
69/CD
HPVs/NNS
is/VBZ
not/RB
known/VBN
,/,
so/RB
that/IN
65/CD
HPVs/NNS
are/VBP
evaluated/VBN
./.
====================
Twenty/CD
among/IN
65/CD
HPVs/NNS
are/VBP
classified/VBN
as/IN
high-risk/JJ
and/CC
the/DT
remaining/VBG
45/CD
are/VBP
classified/VBN
as/IN
low-risk/JJ
,/,
while/IN
there/EX
are/VBP
only/RB
12/CD
high-risk/JJ
HPVs/NNS
in/IN
Table/JJ
2/CD
./.
====================
Since/IN
53/CD
HPVs/NNS
are/VBP
correctly/RB
classified/VBN
,/,
the/DT
accuracy/NN
is/VBZ
81.54/CD
%/NN
./.
====================
At/IN
first/JJ
,/,
this/DT
accuracy/NN
seems/VBZ
reasonable/JJ
./.
====================
However/RB
,/,
four/CD
of/IN
12/CD
misclassified/VBN
cases/NNS
are/VBP
false/JJ
negative/JJ
,/,
and/CC
8/CD
are/VBP
false/JJ
positive/JJ
./.
====================
That/DT
is/VBZ
,/,
this/DT
is/VBZ
not/RB
satisfactory/JJ
because/IN
false/VBP
negatives/NNS
are/VBP
fatal/JJ
as/IN
stated/VBN
above/JJ
./.
====================
The/DT
reasons/NNS
why/WRB
the/DT
method/NN
which/WDT
ignores/VBZ
the/DT
cost/JJ
does/VBZ
not/RB
achieve/VB
high/JJ
performance/NN
can/MD
be/VB
summarized/VBN
into/IN
two/CD
problems/NNS
./.
====================
The/DT
first/JJ
one/CD
is/VBZ
that/DT
too/RB
many/JJ
high-risk/JJ
HPVs/NNS
are/VBP
predicted/VBN
./.
====================
That/DT
is/VBZ
,/,
there/EX
are/VBP
only/RB
12/CD
high-risk/JJ
ones/NNS
in/IN
the/DT
tested/VBN
HPVs/NNS
,/,
but/CC
the/DT
native/JJ
Bayes/NNS
predicted/VBN
20/CD
HPVs/NNS
as/IN
high-/JJ
risk/NN
./.
====================
Though/IN
we/PRP
used/VBD
only/RB
two/CD
low-risk/JJ
HPVs/NNS
,/,
in/IN
fact/NN
there/EX
are/VBP
far/RB
more/RBR
low-risk/JJ
HPVs/NNS
than/IN
high-risk/JJ
HPVs/NNS
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
required/VBN
to/TO
give/VB
a/DT
higher/JJR
cost/NN
to/TO
high-risk/VB
HPVs/NNS
during/IN
training/VBG
./.
====================
The/DT
other/JJ
problem/NN
is/VBZ
that/DT
there/EX
are/VBP
some/DT
HPVs/NNS
that/DT
are/VBP
difficult/JJ
to/TO
determine/VB
their/PRP$
risk/NN
types/NNS
only/RB
by/IN
their/PRP$
textual/JJ
explanation/NN
./.
====================
For/IN
instance/NN
,/,
HPV54/NN
is/VBZ
explained/VBN
by/IN
a/DT
single/JJ
sentence/NN
which/WDT
is/VBZ
``/CD
HPV-54/NN
was/VBD
first/JJ
isolated/VBN
from/IN
a/DT
patient/NN
with/IN
condyloma/NN
acuminata./FW
”/CD
This/DT
problem/NN
is/VBZ
inevitable/JJ
in/IN
text/JJ
classification/NN
./.
====================
Thus/RB
,/,
it/PRP
goes/VBZ
beyond/JJ
interest/NN
of/IN
this/DT
paper/NN
and/CC
should/MD
be/VB
solved/VBN
by/IN
further/JJ
biomedical/JJ
experiments/NNS
./.
====================
In/IN
order/NN
to/TO
consider/VB
the/DT
misclassification/NN
cost/JJS
of/IN
HPV/NN
risk/NN
types/NNS
,/,
we/PRP
adopt/VBP
the/DT
AdaCost/NN
algorithm/NN
(/(
Fan/NN
et/FW
al/JJ
,/,
1999/CD
)/)
./.
====================
The/DT
AdaCost/JJ
is/VBZ
a/DT
variant/JJ
of/IN
AdaBoost/JJ
(/(
Freund/JJ
and/CC
Schapire/NNP
,/,
1996/CD
)/)
that/WDT
uses/VBZ
the/DT
cost/JJ
of/IN
misclassifications/NNS
to/TO
update/VB
the/DT
training/VBG
distribution/NN
on/IN
successive/JJ
boosting/VBG
rounds/NNS
./.
====================
The/DT
algorithm/NN
is/VBZ
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
Let/NN
S/NN
=/JJ
{/CD
(/(
xi/LS
,/,
ci/NNS
,/,
yi/NNP
)/)
,/,
A/DT
,/,
(/(
x/NN
====================
m/NN
,/,
cm/NN
,/,
y/RB
m/NN
)/)
}/CD
be/VB
a/DT
training/JJ
set/NN
where/WRB
g/NN
</JJR
=/JJ
[/(
0,1/CD
]/)
is/VBZ
a/DT
cost/JJ
factor/NN
and/CC
====================
is/VBZ
additionally/RB
given/VBN
to/TO
the/DT
normal/JJ
and/CC
y^/NN
{/CD
-l/JJ
,/,
+l/JJ
}/CD
./.
====================
First/RB
of/IN
all/DT
,/,
the/DT
distribution/NN
of/IN
each/DT
example/NN
is/VBZ
set/NN
to/TO
D/NN
!/CD
====================
(/(
i/LS
)/)
=/JJ
■/CD
When/WRB
t/NN
is/VBZ
an/DT
index/NN
to/TO
show/VB
the/DT
round/NN
of/IN
boosting/VBG
,/,
Dt/NNP
(/(
i/LS
)/)
is/VBZ
the/DT
sampling/JJ
weight/NN
given/VBN
to/TO
(/(
x/CC
‘/CD
>/JJR
c/NN
1/CD
,/,
y/RB
)/)
at/IN
the/DT
/-th/NN
round/NN
./.
====================
And/CC
,/,
a/DT
>/JJR
0/CD
is/VBZ
a/DT
parameter/NN
as/IN
a/DT
weight/NN
for/IN
weak/JJ
learner/NN
ht/NN
at/IN
the/DT
r-th/NN
round/NN
,/,
and/CC
its/PRP$
value/NN
is/VBZ
given/VBN
as/IN
====================
where/WRB
ZiD/NN
(/(
i/LS
)/)
yihi/NN
(/(
xt/NN
)/)
f/VBP
}/CD
(/(
i/LS
)/)
./.
====================
And/CC
,/,
0/CD
(/(
i/LS
)/)
is/VBZ
a/DT
cost/JJ
adjustment/JJ
====================
function/NN
with/IN
two/CD
arguments/NNS
,/,
signfy^xi/NN
)/)
)/)
and/CC
a/DT
./.
====================
If/IN
h/NN
t/NN
(/(
x/NN
>/JJR
)/)
is/VBZ
====================
correct/JJ
,/,
then/RB
ffli/FW
)/)
=/JJ
-0.5a/CD
+/JJ
0.5/CD
,/,
otherwise/RB
0/CD
(/(
i/LS
)/)
=/JJ
0.5a/CD
+/JJ
0.5/CD
./.
====================
where/WRB
Wd*/NN
denotes/VBZ
the/DT
Wh/NN
word/NN
in/IN
the/DT
document/NN
d/FW
}/CD
,/,
the/DT
====================
weight/NN
of/IN
word/NN
occurring/VBG
in/IN
document/JJ
d/FW
,/,
and/CC
I/NN
di/NN
I/NN
is/VBZ
the/DT
number/NN
of/IN
words/NNS
in/IN
the/DT
document/NN
./.
====================
Thus/RB
,/,
when/WRB
assuming/VBG
P/NN
(/(
l/JJ
di/NN
I/NN
)/)
is/VBZ
uniform/JJ
,/,
the/DT
best/JJS
class/NN
y*/CD
of/IN
a/DT
document/JJ
di/NN
is/VBZ
determined/VBN
by/IN
====================
The/DT
main/JJ
difference/NN
between/IN
AdaBoost/NN
and/CC
AdaCost/NN
is/VBZ
how/WRB
the/DT
distribution/NN
Dt/NN
is/VBZ
updated/VBN
./.
====================
AdaCost/RB
has/VBZ
an/DT
====================
additional/JJ
cost/NN
adjustment/JJ
factor/NN
in/IN
updating/VBG
D/NN
t/NN
(/(
see/VB
step/NN
4/CD
====================
in/IN
Fig/NN
./.
====================
1/CD
)/)
./.
====================
As/IN
AdaBoost/NN
does/VBZ
,/,
the/DT
weight/NN
of/IN
an/DT
instance/NN
will/MD
be/VB
increased/VBN
if/IN
it/PRP
is/VBZ
misclassified/VBN
./.
====================
Similarly/RB
,/,
its/PRP$
weight/NN
will/MD
be/VB
decreased/VBN
otherwise/RB
./.
====================
However/RB
,/,
the/DT
weight/NN
change/NN
is/VBZ
affected/VBN
by/IN
the/DT
value/NN
of/IN
the/DT
cost/JJ
factor/NN
./.
====================
When/WRB
an/DT
instance/NN
has/VBZ
a/DT
high/JJ
cost/NN
factor/NN
,/,
the/DT
weight/NN
change/NN
will/MD
be/VB
greater/JJR
than/IN
that/DT
with/IN
a/DT
low/JJ
cost/JJ
factor/NN
./.
====================
We/PRP
have/VBP
previously/RB
proposed/VBN
the/DT
BayesBoost/JJ
algorithm/NN
and/CC
showed/VBD
that/IN
it/PRP
gives/VBZ
great/JJ
efficiency/NN
in/IN
text/NN
filtering/VBG
(/(
Kim/NN
et/FW
al./FW
,/,
2000/CD
)/)
./.
====================
It/PRP
uses/VBZ
naive/JJ
Bayes/NNS
classifiers/NNS
as/IN
its/PRP$
weak/JJ
learner/NN
within/IN
AdaBoost/NN
./.
====================
Assume/DT
that/DT
a/DT
document/JJ
dt/IN
is/VBZ
composed/VBN
of/IN
a/DT
sequence/NN
of/IN
words/NNS
which/WDT
is/VBZ
wn/VBN
,/,
Wi2/NN
,/,
A/DT
,/,
Wi\dii/NNP
,/,
and/CC
the/DT
words/NNS
in/IN
a/DT
document/JJ
are/VBP
mutually/RB
independent/JJ
one/CD
another/DT
and/CC
the/DT
probability/NN
of/IN
a/DT
word/NN
is/VBZ
independent/JJ
of/IN
its/PRP$
position/NN
within/IN
the/DT
document/JJ
./.
====================
Though/IN
these/DT
assumptions/NNS
are/VBP
not/RB
true/JJ
in/IN
real/JJ
situations/NNS
,/,
naive/JJ
Bayes/NNS
classifiers/NNS
showed/VBD
rather/RB
good/JJ
performance/NN
in/IN
text/JJ
classification/NN
(/(
McCallum/NN
and/CC
Nigam/JJ
,/,
1998/CD
)/)
./.
====================
Due/IN
to/TO
the/DT
independence/NN
assumption/NN
,/,
the/DT
probability/NN
that/DT
a/DT
document/JJ
di/NN
is/VBZ
generated/VBN
from/IN
the/DT
class/NN
yj/CD
can/MD
be/VB
expressed/VBN
as/IN
====================
In/IN
order/NN
to/TO
calculate/JJ
this/DT
probability/NN
,/,
we/PRP
need/VBD
to/TO
determine/VB
P/NN
(/(
wk\yj/NN
;/:
§/RB
)/)
and/CC
P/NN
(/(
y/RB
|/CD
§/CD
)/)
./.
====================
These/DT
two/CD
values/NNS
can/MD
be/VB
estimated/VBN
as/IN
====================
Here/RB
,/,
IVl/JJ
is/VBZ
the/DT
size/NN
of/IN
vocabulary/JJ
./.
====================
One/CD
of/IN
the/DT
advantages/NNS
of/IN
using/VBG
naive/JJ
Bayes/NNS
classifier/NN
as/IN
a/DT
weak/JJ
learner/NN
is/VBZ
that/DT
the/DT
naive/JJ
Bayes/NNS
utilizes/VBZ
term/NN
weights/NNS
such/JJ
as/IN
term/NN
frequency/NN
naturally/RB
./.
====================
Moreover/RB
,/,
because/IN
it/PRP
is/VBZ
a/DT
probabilistic/JJ
model/NN
,/,
it/PRP
provides/VBZ
a/DT
natural/JJ
measure/NN
for/IN
calculating/JJ
confidence/NN
ratios/NNS
in/IN
AdaBoost/JJ
./.
====================
Thus/RB
,/,
in/IN
this/DT
paper/NN
,/,
we/PRP
also/RB
use/VBP
naive/JJ
Bayes/NNS
classifier/NN
as/IN
a/DT
weak/JJ
learner/NN
of/IN
AdaCost/JJ
./.
====================
In/IN
general/JJ
,/,
the/DT
research/NN
in/IN
biomedical/JJ
domain/NN
starts/NNS
from/IN
investigating/VBG
previous/JJ
studies/NNS
in/IN
PubMed/JJ
designed/VBN
to/TO
====================
provide/VBP
access/RB
to/TO
citations/NNS
from/IN
biomedical/JJ
literature/NN
and/CC
available/JJ
via/IN
the/DT
NCBI/NN
Entrez/NN
retrieval/JJ
system/NN
developed/VBD
by/IN
National/JJ
Center/JJ
for/IN
Biotechnology/NN
Information/NN
(/(
NCBI/NN
)/)
at/IN
the/DT
National/JJ
Library/JJ
of/IN
Medicine/NN
(/(
NLM/NN
)/)
located/JJ
at/IN
the/DT
National/JJ
Institutes/NNS
of/IN
Health/NN
(/(
NIH/NN
)/)
./.
====================
Most/JJS
bioinformatics/NNS
research/NN
that/IN
handles/NNS
text/NN
information/NN
has/VBZ
focused/VBN
on/IN
PubMed/JJ
as/IN
its/PRP$
resource/NN
,/,
because/IN
it/PRP
includes/VBZ
most/JJS
summaries/VBZ
and/CC
citations/NNS
about/RB
biomedical/JJ
literature/NN
./.
====================
However/RB
,/,
learning/VBG
HPV/NN
risk/NN
types/NNS
from/IN
PubMed/JJ
is/VBZ
not/RB
an/DT
====================
easy/RB
work/NN
./.
====================
The/DT
difficulties/NNS
can/MD
be/VB
summarized/VBN
with/IN
two/CD
reasons/NNS
./.
====================
•/CD
The/DT
PubMed/JJ
data/NNS
are/VBP
too/RB
sparse/JJ
./.
====================
For/IN
example/NN
,/,
there/EX
are/VBP
3,797/CD
articles/NNS
about/RB
HPV/NN
and/CC
cervical/JJ
cancer/NN
in/IN
PubMed/JJ
,/,
but/CC
most/JJS
of/IN
them/PRP
do/VBP
not/RB
discuss/VB
the/DT
risk/NN
of/IN
HPV/NN
directly/RB
./.
====================
Thus/RB
,/,
it/PRP
is/VBZ
difficult/JJ
to/TO
capture/NN
the/DT
risk/NN
of/IN
HPV/NN
from/IN
the/DT
articles/NNS
./.
====================
In/IN
addition/NN
,/,
the/DT
term/NN
distribution/NN
is/VBZ
totally/RB
different/JJ
according/VBG
to/TO
the/DT
interest/NN
of/IN
the/DT
articles/NNS
./.
====================
•/CD
Poor/JJ
performance/NN
of/IN
NLP/NN
techniques/NNS
====================
The/DT
current/JJ
natural/JJ
language/NN
processing/NN
(/(
NLP/NN
)/)
techniques/NNS
are/VBP
not/RB
for/IN
text/NN
understanding/NN
yet/RB
./.
====================
They/PRP
can/MD
not/RB
provide/VB
even/RB
correct/VB
syntactic/JJ
information/NN
./.
====================
The/DT
best/JJS
thing/VBG
we/PRP
can/MD
expect/VB
from/IN
NLP/NN
techniques/NNS
is/VBZ
morphological/JJ
analysis/NN
and/CC
part-of-speech/JJ
tagging/VBG
./.
====================
Thus/RB
,/,
the/DT
articles/NNS
need/VBD
to/TO
be/VB
refined/VBN
for/IN
further/JJ
study/NN
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
use/VBP
the/DT
HPV/NN
Sequence/NN
Database/NN
?/.
====================
in/IN
Los/NN
Alamos/NN
National/JJ
Laboratory/JJ
as/IN
a/DT
dataset/NN
./.
====================
This/DT
papillomavirus/NN
database/NN
is/VBZ
an/DT
extension/NN
of/IN
the/DT
HPV/NN
compendiums/NNS
published/VBN
in/IN
1994/CD
,/,
1995/CD
,/,
1996/CD
,/,
and/CC
1997/CD
and/CC
provides/VBZ
the/DT
complete/JJ
list/NN
of/IN
'papillomavirus/NN
types/NNS
and/CC
hosts/NNS
and/CC
the/DT
records/NNS
for/IN
each/DT
unique/JJ
papillomavirus/NN
type/NN
./.
====================
An/DT
example/NN
of/IN
the/DT
data/NNS
made/VBD
from/IN
this/DT
database/NN
is/VBZ
given/VBN
in/IN
Fig/NN
./.
====================
2/CD
./.
====================
This/DT
example/NN
is/VBZ
for/IN
HPV80/CD
and/CC
consists/VBZ
of/IN
three/CD
parts/NNS
:/:
definition/NN
,/,
source/NN
,/,
and/CC
comment/JJ
./.
====================
The/DT
definition/NN
indicates/VBZ
the/DT
HPV/NN
type/NN
,/,
the/DT
source/NN
explains/VBZ
where/WRB
the/DT
information/NN
for/IN
this/DT
HPV/NN
is/VBZ
obtained/VBN
,/,
and/CC
the/DT
comment/JJ
gives/VBZ
the/DT
explanation/NN
for/IN
this/DT
HPV/NN
./.
====================
To/TO
measure/VB
the/DT
performance/NN
of/IN
the/DT
results/NNS
in/IN
the/DT
experiments/NNS
below/IN
,/,
we/PRP
manually/RB
classified/VBN
HPV/NN
risk/NN
types/NNS
using/VBG
the/DT
1997/CD
version/NN
of/IN
Human/JJ
Papillomaviruses/NNS
compendium/NN
and/CC
the/DT
comment/JJ
in/IN
the/DT
records/NNS
of/IN
HPV/NN
types/NNS
./.
====================
The/DT
classifying/NN
procedure/NN
is/VBZ
as/IN
follows/VBZ
./.
====================
First/RB
,/,
we/PRP
divided/VBD
roughly/RB
HPV/NN
types/NNS
by/IN
the/DT
groups/NNS
in/IN
the/DT
1997/CD
version/NN
of/IN
Human/JJ
Papillomaviruses/NNS
compendium/NN
./.
====================
These/DT
groups/NNS
are/VBP
shown/VBN
in/IN
Fig/NN
./.
====================
3/CD
./.
====================
This/DT
tree/JJ
,/,
which/WDT
contains/VBZ
108/CD
Papilloma/NN
Virus/NN
(/(
PV/NN
)/)
sequences/NNS
,/,
was/VBD
computed/VBN
for/IN
the/DT
L1/NN
consensus/NN
primer/NN
region/NN
(/(
CPR/NN
)/)
using/VBG
neighbor/JJ
joining/VBG
method/NN
and/CC
a/DT
distance/NN
matrix/NN
calculated/VBN
with/IN
a/DT
modified/JJ
Kimura/NN
2-parameter/JJ
model/NN
(/(
transition/transversion/NN
ratio/NN
2.0/CD
)/)
./.
====================
Neighbor-joining/VBG
analysis/NN
is/VBZ
a/DT
convenient/JJ
and/CC
rapid/JJ
way/NN
to/TO
get/VB
an/DT
initial/JJ
estimate/NN
of/IN
branching/VBG
relationships/NNS
,/,
especially/RB
when/WRB
a/DT
large/JJ
number/NN
of/IN
taxa/NN
are/VBP
involved/VBN
./.
====================
In/IN
the/DT
figure/NN
,/,
the/DT
outermost/JJ
wide/JJ
gray/NN
arcs/NNS
show/VBP
the/DT
five/CD
PV/JJ
supergroups/NNS
(/(
A-E/NN
)/)
./.
====================
Each/DT
tree/NN
branch/NN
is/VBZ
labeled/VBN
with/IN
an/DT
abbreviated/JJ
sequence/NN
name/NN
./.
====================
For/IN
HP/NN
Vs/NNS
the/DT
‘/NN
type/NN
’/CD
number/NN
alone/RB
is/VBZ
given/VBN
in/IN
most/JJS
cases/NNS
,/,
so/RB
the/DT
branch/NN
labeled/VBN
40/CD
is/VBZ
thatofHPV40/DT
./.
====================
</JJR
source/NN
>/JJR
====================
Human/JJ
papillomavirus/NN
type/NN
80/CD
./.
====================
</JJR
/source/NN
>/JJR
====================
</JJR
conunent/JJ
>/JJR
====================
The/DT
DNA/NN
genome/NN
of/IN
HPV80/CD
(/(
HPV15-related/JJ
)/)
was/VBD
isolated/VBN
from/IN
histologically/RB
normal/JJ
skin/NN
,/,
cloned/VBN
,/,
and/CC
sequenced/VBN
./.
====================
HPV80/CD
is/VBZ
most/RBS
similar/JJ
to/TO
HPV/NN
15/CD
,/,
and/CC
falls/NNS
within/IN
one/CD
of/IN
the/DT
two/CD
major/JJ
branches/NNS
of/IN
the/DT
B1/NN
or/CC
Cutaneous/EV/JJ
clade/NN
./.
====================
The/DT
E7/NN
,/,
El/NNP
,/,
and/CC
E4/NN
orfs/NNS
,/,
as/IN
well/RB
as/IN
the/DT
URR/NN
,/,
of/IN
HPV/NN
15/CD
and/CC
HPV80/CD
share/VBP
sequence/NN
similarities/NNS
higher/JJR
than/IN
90/CD
%/NN
,/,
while/IN
in/IN
the/DT
usually/RB
more/RBR
conservative/JJ
LI/NN
orf/IN
the/DT
nucleotide/NN
similarity/NN
is/VBZ
only/RB
87/CD
%/NN
./.
====================
A/DT
detailed/JJ
comparative/JJ
sequence/NN
analysis/NN
of/IN
HPV80/CD
revealed/VBD
features/NNS
characteristic/JJ
of/IN
a/DT
truly/RB
cutaneous/JJ
HPV/NN
type/NN
[/(
362/CD
]/)
./.
====================
Notice/RB
in/IN
the/DT
alignment/NN
below/IN
that/DT
HPV80/CD
compares/NNS
closely/RB
to/TO
the/DT
cutaneous/JJ
types/NNS
HPV/NN
15/CD
and/CC
HPV49/NN
in/IN
the/DT
important/JJ
E7/NN
functional/JJ
regions/NNS
CR1/NN
,/,
pRb/NN
binding/VBG
site/NN
,/,
and/CC
CR2/NN
./.
====================
HPV/NN
80/CD
is/VBZ
distinctly/RB
different/JJ
from/IN
the/DT
high-risk/JJ
mucosal/JJ
viruses/NNS
represented/VBN
by/IN
HPV/NN
16/CD
./.
====================
The/DT
locus/NN
as/IN
defined/VBN
by/IN
GenBank/NN
is/VBZ
HPVY15176/CD
./.
====================
Mvuiiuiiaiu*/DT
====================
Second/RB
,/,
if/IN
the/DT
type/NN
of/IN
the/DT
group/NN
is/VBZ
skin-related/VBN
or/CC
cutaneous/JJ
HPV/NN
,/,
the/DT
members/NNS
of/IN
the/DT
group/NN
are/VBP
classified/VBN
into/IN
low-risk/JJ
type/NN
./.
====================
Third/RB
,/,
if/IN
the/DT
group/NN
is/VBZ
known/VBN
to/TO
be/VB
high-/JJ
risk/NN
type/NN
of/IN
cervical/JJ
cancer-related/JJ
HPV/NN
,/,
the/DT
members/NNS
of/IN
the/DT
group/NN
are/VBP
classified/VBN
into/IN
high-risk/JJ
type/NN
./.
====================
Lastly/RB
,/,
we/PRP
used/VBD
the/DT
comment/JJ
of/IN
HPV/NN
types/NNS
to/TO
classify/VB
some/DT
types/NNS
difficult/JJ
to/TO
be/VB
classified/VBN
./.
====================
Table/JJ
2/CD
shows/VBZ
the/DT
summarized/VBN
classification/NN
of/IN
HPVs/NNS
according/VBG
to/TO
its/PRP$
risk/NN
./.
====================
In/IN
the/DT
all/DT
experiments/NNS
below/IN
,/,
we/PRP
used/VBD
only/RB
</JJR
comment/JJ
>/JJR
part/NN
./.
====================
The/DT
comment/JJ
for/IN
a/DT
HPV/NN
type/NN
can/MD
be/VB
considered/VBN
as/IN
a/DT
document/JJ
in/IN
text/NN
classification/NN
./.
====================
Therefore/RB
,/,
each/DT
HPV/NN
type/NN
is/VBZ
represented/VBN
as/IN
a/DT
vector/NN
of/IN
which/WDT
elements/NNS
are/VBP
tf/VBN
•/CD
idf/IN
====================
values/NNS
./.
====================
In/IN
tf/NN
•/CD
idf/NN
N/NN
(/(
w/NN
jf/IN
di/NN
)/)
of/IN
Equation/NN
(/(
1/CD
)/)
,/,
the/DT
weight/NN
of/IN
a/DT
====================
word/NN
Wj/NN
appeared/VBD
in/IN
the/DT
document/NN
di/NN
is/VBZ
given/VBN
as/IN
====================
where/WRB
$/CD
is/VBZ
the/DT
frequency/NN
of/IN
w/JJ
,/,
in/IN
di/JJ
and/CC
n/NN
is/VBZ
the/DT
number/NN
of/IN
documents/NNS
where/WRB
w/JJ
,/,
occurs/VBZ
at/IN
least/JJS
once/RB
./.
====================
When/WRB
we/PRP
stemmed/VBD
the/DT
documents/NNS
using/VBG
the/DT
Porter/NN
s/NNS
algorithm/NN
(/(
Porter/NN
,/,
1980/CD
)/)
and/CC
removed/VBD
words/NNS
from/IN
the/DT
stop-/NN
====================
list/NN
,/,
the/DT
size/NN
of/IN
vocabulary/JJ
is/VBZ
just/RB
1,434/CD
./.
====================
Thus/RB
,/,
each/DT
document/VBP
is/VBZ
represented/VBN
as/IN
a/DT
1,434-dimensional/JJ
vector/NN
./.
====================
Text/RB
classification/NN
has/VBZ
various/JJ
measures/NNS
to/TO
evaluate/VB
its/PRP$
performance/NN
./.
====================
One/CD
of/IN
these/DT
is/VBZ
the/DT
break-even/JJ
point/NN
(/(
Lewis/NN
,/,
1995/CD
)/)
./.
====================
However/RB
,/,
Schapire/NNP
et/FW
al/JJ
./.
====================
(/(
1998/CD
)/)
asserted/VBD
that/DT
the/DT
break-even/JJ
points/NNS
are/VBP
not/RB
very/RB
suitable/JJ
for/IN
measuring/VBG
the/DT
performance/NN
of/IN
classification/NN
algorithms/NNS
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
evaluate/VBP
the/DT
classification/NN
performance/NN
using/VBG
the/DT
contingency/NN
table/JJ
method/NN
./.
====================
In/IN
this/DT
method/NN
,/,
recall/NN
and/CC
precision/NN
are/VBP
defined/VBN
as/IN
follows/VBZ
:/:
====================
recall/DT
=/JJ
•/CD
100/CD
%/NN
====================
precision/NN
=/JJ
•/CD
100/CD
%/NN
(/(
3/CD
)/)
====================
accuracy/NN
=/JJ
'/``
100/CD
%/NN
====================
where/WRB
a/DT
,/,
b/LS
,/,
c/NN
and/CC
d/FW
are/VBP
defined/VBN
in/IN
Table/JJ
3/CD
./.
====================
The/DT
Fa-score/NN
which/WDT
combines/VBZ
precision/NN
and/CC
recall/NN
is/VBZ
defined/VBN
as/IN
====================
//:
?/.
====================
2/CD
•/CD
recall/NN
+/JJ
precision/NN
100/CD
%/NN
====================
where/WRB
0/CD
is/VBZ
the/DT
weight/NN
of/IN
recall/JJ
relative/JJ
to/TO
precision/NN
./.
====================
We/PRP
use/VBP
//:
?/.
====================
Since/IN
we/PRP
have/VBP
only/RB
74/CD
HPV/NN
types/NNS
and/CC
the/DT
explanation/NN
of/IN
each/DT
HPV/NN
is/VBZ
relatively/RB
short/JJ
,/,
leave-one-out/RB
(/(
LOO/NN
)/)
cross-/JJ
validation/NN
is/VBZ
used/VBN
to/TO
determine/VB
the/DT
performance/NN
of/IN
the/DT
proposed/JJ
method/NN
./.
====================
We/PRP
normalized/VBD
each/DT
cost/JJS
a/DT
to/TO
[/(
0/CD
,/,
1/CD
]/)
./.
====================
That/DT
is/VBZ
,/,
the/DT
cost/JJ
for/IN
low-risk/JJ
HPVs/NNS
is/VBZ
set/NN
to/TO
0.1/CD
when/WRB
the/DT
cost/JJ
for/IN
high-risk/JJ
HPVs/NNS
is/VBZ
set/NN
to/TO
0.9/CD
./.
====================
Fig/NN
./.
====================
4/CD
demonstrates/VBZ
the/DT
performance/NN
of/IN
AdaCost/NN
./.
====================
The/DT
graphs/NNS
in/IN
this/DT
figure/NN
show/VBP
the/DT
accuracy/NN
and/CC
F-score/NN
according/VBG
to/TO
the/DT
round/NN
of/IN
AdaCost/JJ
./.
====================
Each/DT
graph/NN
represents/VBZ
the/DT
ratio/NN
of/IN
costs/NNS
for/IN
high-risk/JJ
and/CC
low-risk/JJ
HPVs/NNS
./.
====================
For/IN
instance/NN
,/,
figure/NN
(/(
a/DT
)/)
imposes/VBZ
0.1/CD
on/IN
high-risk/JJ
HPVs/NNS
and/CC
0.9/CD
on/IN
low-risk/JJ
HPVs/NNS
./.
====================
Because/IN
the/DT
costs/NNS
in/IN
figure/NN
(/(
e/NN
)/)
are/VBP
both/CC
set/NN
to/TO
0.5/CD
,/,
it/PRP
is/VBZ
the/DT
performance/NN
of/IN
the/DT
AdaBoost/NN
./.
====================
Figures/NNS
(/(
a/DT
)/)
-/:
(/(
d/FW
)/)
plot/NN
the/DT
performance/NN
when/WRB
lower/JJR
costs/NNS
are/VBP
imposed/VBN
on/IN
high-risk/JJ
HPVs/NNS
than/IN
those/DT
on/IN
low-risk/JJ
HPVs/NNS
./.
====================
And/CC
,/,
figures/NNS
(/(
f/IN
)/)
-/:
(/(
i/LS
)/)
plot/NN
the/DT
performance/NN
when/WRB
higher/JJR
costs/NNS
are/VBP
imposed/VBN
on/IN
high-risk/JJ
HPVs/NNS
./.
====================
Generally/RB
,/,
when/WRB
we/PRP
set/VBP
different/JJ
costs/NNS
to/TO
low-risk/JJ
and/CC
high-risk/VBP
HPVs/NNS
,/,
higher/JJR
performance/IN
is/VBZ
obtained/VBN
than/IN
AdaBoost/NN
shown/VBN
by/IN
figure/NN
(/(
e/NN
)/)
except/IN
the/DT
extreme/JJ
cases/NNS
represented/VBD
by/IN
figure/NN
(/(
a/DT
)/)
and/CC
(/(
i/LS
)/)
./.
====================
Among/IN
nine/CD
graphs/NNS
,/,
figure/NN
(/(
h/NN
)/)
shows/VBZ
the/DT
best/JJS
performance/NN
./.
====================
It/PRP
implies/VBZ
that/IN
0.8/CD
is/VBZ
the/DT
best/JJS
cost/JJS
for/IN
high-risk/JJ
HPVs/NNS
./.
====================
It/PRP
is/VBZ
also/RB
interesting/VBG
to/TO
see/VB
====================
that/DT
figure/NN
(/(
a/DT
)/)
shows/VBZ
the/DT
worst/NN
performance/NN
./.
====================
That/DT
is/VBZ
,/,
in/IN
this/DT
case/NN
AdaCost/NN
shows/VBZ
worse/NN
performance/NN
than/IN
AdaBoost/NN
./.
====================
Therefore/RB
,/,
if/IN
we/PRP
impose/VBP
wrong/JJ
cost/JJS
,/,
we/PRP
may/MD
obtain/VB
worse/NN
result/NN
./.
====================
Table/JJ
4/CD
summarizes/VBZ
the/DT
graphs/NNS
in/IN
Fig/NN
./.
====================
4/CD
./.
====================
These/DT
results/NNS
are/VBP
obtained/VBN
when/WRB
50/CD
weak/JJ
learners/NNS
are/VBP
used/VBN
in/IN
each/DT
AdaCost/NN
./.
====================
The/DT
accuracy/NN
is/VBZ
similar/JJ
with/IN
various/JJ
costs/NNS
,/,
but/CC
different/JJ
costs/NNS
show/VBP
different/JJ
performance/NN
on/IN
F-score/NN
./.
====================
As/IN
shown/VBN
in/IN
Equation/NN
(/(
3/CD
)/)
,/,
precision/NN
and/CC
recall/JJ
are/VBP
related/JJ
with/IN
the/DT
number/NN
of/IN
found/VBN
high-risk/VBP
HPVs/NNS
while/IN
accuracy/NN
is/VBZ
related/JJ
with/IN
the/DT
number/NN
of/IN
correctly/RB
predicted/VBN
HPVs/NNS
including/VBG
both/CC
low-risk/JJ
and/CC
high-risk/VBP
HPVs/NNS
./.
====================
In/IN
our/PRP$
experiments/NNS
,/,
F-scores/NNS
are/VBP
higher/JJR
than/IN
accuracies/NNS
,/,
which/WDT
implies/VBZ
that/IN
less/RBR
high-risk/JJ
HPVs/NNS
are/VBP
missed/VBN
by/IN
the/DT
====================
proposed/VBN
method/NN
./.
====================
Table/JJ
5/CD
shows/VBZ
the/DT
predicted/VBN
risk/NN
type/NN
for/IN
the/DT
HPV/NN
types/NNS
whose/WP$
risks/NNS
are/VBP
not/RB
known/VBN
exactly/RB
./.
====================
These/DT
HPVs/NNS
are/VBP
described/VBN
as/IN
‘/CD
?/.
’/CD
in/IN
Table/JJ
2/CD
./.
====================
According/VBG
to/TO
previous/JJ
====================
research/DT
on/IN
HPV/NN
(/(
Chan/NNP
et/FW
al./FW
,/,
1997/CD
;/:
Favre/RB
et/FW
al./FW
,/,
1990/CD
;/:
Meyer/NNP
et/FW
al./FW
,/,
1998/CD
;/:
Nuovo/FW
et/FW
al./FW
,/,
1988/CD
)/)
,/,
HPV70/NN
seems/VBZ
to/TO
be/VB
misclassified/VBN
./.
====================
This/DT
is/VBZ
because/IN
the/DT
comment/JJ
for/IN
HPV70/NN
does/VBZ
not/RB
describe/VB
its/PRP$
risk/NN
but/CC
because/IN
of/IN
its/PRP$
lack/NN
of/IN
biomedical/JJ
research/NN
it/PRP
explains/VBZ
only/RB
that/DT
it/PRP
is/VBZ
found/VBN
at/IN
the/DT
cervix/JJ
of/IN
patients/NNS
and/CC
its/PRP$
sequence/NN
is/VBZ
analyzed/VBN
./.
====================
This/DT
paper/NN
proposed/VBN
a/DT
practical/JJ
method/NN
to/TO
determine/VB
the/DT
risk/NN
type/NN
of/IN
Human/JJ
Papillomavirus/NN
./.
====================
In/IN
classifying/VBG
the/DT
risk/NN
type/NN
,/,
it/PRP
is/VBZ
important/JJ
to/TO
distinguish/VB
false/VBP
negatives/NNS
from/IN
false/JJ
positives/VBZ
,/,
where/WRB
false-negatives/VBZ
are/VBP
high-risk/JJ
HPVs/NNS
that/DT
are/VBP
misclassified/VBN
as/IN
low-risk/JJ
and/CC
false/VBP
positives/VBZ
are/VBP
low-risk/JJ
HPVs/NNS
misclassified/VBN
as/IN
high-risk/JJ
./.
====================
For/IN
this/DT
purpose/NN
,/,
we/PRP
set/VBP
different/JJ
costs/NNS
for/IN
low-risk/JJ
and/CC
high-risk/VBP
HPVs/NNS
./.
====================
As/IN
a/DT
learning/VBG
algorithm/NN
,/,
we/PRP
adopted/VBD
AdaCost/NN
and/CC
showed/VBD
empirically/RB
that/DT
it/PRP
outperforms/VBZ
AdaBoost/NN
which/WDT
does/VBZ
not/RB
consider/VB
learning/VBG
cost/JJS
./.
====================
In/IN
addition/NN
,/,
the/DT
experimental/JJ
results/NNS
gave/VBP
higher/JJR
F-score/NN
than/IN
accuracy/NN
,/,
and/CC
it/PRP
means/NNS
that/DT
more/RBR
high-risk/JJ
HPVs/NNS
are/VBP
found/VBN
by/IN
AdaCost/NN
./.
====================
This/DT
result/NN
is/VBZ
important/JJ
because/IN
high-risk/VBP
HPVs/NNS
,/,
as/IN
stated/VBN
above/JJ
,/,
should/MD
not/RB
be/VB
missed/VBN
./.
====================
Since/IN
HPV/NN
is/VBZ
known/VBN
as/IN
the/DT
main/JJ
cause/JJ
of/IN
cervical/JJ
cancer/NN
,/,
high-risk/VBP
HPVs/NNS
must/MD
be/VB
found/VBN
for/IN
further/JJ
medical/JJ
investigation/NN
of/IN
the/DT
patients/NNS
./.
====================
Our/PRP$
results/NNS
can/MD
be/VB
used/VBN
as/IN
fundamental/JJ
information/NN
to/TO
design/VB
the/DT
DNA-chips/NNS
for/IN
diagnosing/VBG
the/DT
presence/NN
of/IN
HPV/NN
in/IN
cervical/JJ
cancer/NN
patients/NNS
./.
====================
Because/IN
the/DT
cost/JJ
is/VBZ
too/RB
high/JJ
to/TO
test/VB
all/DT
HPV/NN
types/NNS
,/,
the/DT
results/NNS
presented/VBN
in/IN
this/DT
paper/NN
reduce/VBP
time/NN
and/CC
monetary/JJ
cost/JJ
to/TO
know/VB
their/PRP$
relation/NN
with/IN
cervical/JJ
cancer/NN
./.
====================
